Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Technologies changes name

This article was originally published in The Tan Sheet

Executive Summary

The Cold-FX manufacturer changes its name to Afexa Life Sciences as part of a broader rebranding plan. CV Technologies "did not convey our rigorous life sciences orientation, or support our plans to leverage our market-leading product as we launch new ones," Executive Chairman Jack Moffatt says April 1 after shareholders approved the name change. The Canadian company said in November that it may submit a new drug application to FDA and look to grow its presence the U.S. market (1"The Tan Sheet" Nov. 24, 2008, p. 9)

You may also be interested in...

NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections

CV Technologies would consider submitting a new drug application for its American ginseng extract following a National Cancer Institute-sponsored phase III trial on the effects of the ingredient on acute respiratory infection in certain leukemia patients

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts